GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)

Trial Profile

GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Antithrombotics (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions
  • Acronyms GLORIA-AF
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Feb 2017 Results of phase II part of this study (n=15092) published in the Journal of the American College of Cardiology
    • 04 Dec 2016 The results were presented at the American Society of Hematology (ASH) Annual Meeting, as reported by Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top